PHASE II TRIAL OF IV SODIUM PHENYLACETATE IN B CELL CLL

这项研究的目标是1)了解药物钠 苯乙酸酯(NPA)，有助于治疗慢性淋巴细胞白血病 和非霍奇金淋巴瘤，以及2)观察药物的副作用 当连续给药一段时间后引起的。 本研究利用苯乙酸钠(NPA)持续输注 对于复发的非霍奇金淋巴瘤患者，为期6个月， 骨髓瘤和慢性淋巴细胞白血病。我们已经找到了这种药物来 一旦患者达到最佳剂量，就能很好地耐受 毒品。急性副作用包括嗜睡、耳鸣和 听力下降，还有恶心。这些都是与剂量和分辨率相关的 在扣留药物后24-48小时内。从未有过 严重的器官毒性，并且该药物不具有骨髓抑制作用。 目前的计划是提议对这类药物进行更多的试验 与常规化疗药物联合使用。一封……的信 意图正在制定中。

The goals of this research study are 1) to learn if the drug, sodium phenylacetate (NaPA), is helpful against chronic lymphocytic leukemia and non-Hodgkin's lymphoma, and 2) to look at the side effects the drug causes when given over continued periods of time. This study utilizes sodium phenylacetate (NaPA) by continuous infusion for 6 months for patients with relapsed non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia. We have found the drug to be well-tolerated once the patient has achieved the optimal dose of the drug. Acute side effects have consisted of somnolence, tinnitis and decreased hearing, and nausea. These are dose-related and resolve within 24-48 hours after the drug is held. There have been no other significant organ toxicities and the drug is not myelosuppressive. Current plans are to propose additional trials of this class of drugs in combination with conventional chemotherapy agents. A Letter of Intent is being formulated.